Endocannabinoids Can Block Tumor Blood Supply and Spread in Multiple Cancer Types | Research

The takeaway

Research shows endocannabinoids inhibit tumor growth not just by killing cancer cells directly but by blocking angiogenesis (new blood vessel formation), cell migration, and metastasis across multiple cancer types, with a favorable safety profile.

Read this if you want to understand the emerging research on how the endocannabinoid system might fight cancer beyond just managing symptoms.

Endocannabinoids suppress tumors through multiple mechanisms: growth, angiogenesis, migration, and metastasis

What the researchers found

This review highlighted an emerging area of endocannabinoid cancer research beyond the previously known effects on tumor cell growth and death. New evidence showed endocannabinoids can also suppress angiogenesis (the formation of new blood vessels that tumors need to grow), inhibit cancer cell migration, and block metastasis (tumor spreading) across different cancer types.

The endocannabinoid system was positioned as a potential therapeutic target that acts on multiple aspects of cancer progression simultaneously. Unlike many anti-cancer drugs, cannabinoids have a favorable safety profile with low toxicity, and are already used in cancer patients for symptom management (appetite stimulation, anti-nausea, pain relief).

The dual utility of cannabinoids, potentially fighting cancer while also managing cancer treatment side effects, was noted as particularly appealing.

Why it matters

The ability to block tumor blood supply and spreading represents a fundamentally different anti-cancer mechanism from direct cell killing. If endocannabinoid-based treatments can slow tumor vascularization and metastasis while being well-tolerated, they could complement existing cancer therapies.

The numbers in context

Endocannabinoids shown to inhibit: cancer cell growth, apoptosis induction, angiogenesis, cell migration, metastasis. Multiple cancer types studied. Existing clinical use for: appetite stimulation, anti-nausea, pain relief.

How the study worked

Narrative review of emerging research on endocannabinoid effects on tumor angiogenesis, cell migration, and metastasis. Covered in vitro and in vivo studies across multiple cancer types.

What this study cannot tell us

Evidence primarily from cell culture and animal models. No clinical evidence that endocannabinoids or cannabinoids treat cancer in humans. The "good safety profile" comparison is against cytotoxic chemotherapy, setting a low bar. Anti-tumor doses may differ from symptom management doses.

How to read the evidence

Narrative review of preclinical research. Strong mechanistic data but no clinical evidence for anti-cancer effects in humans.

When this study was published

Published in 2007. Preclinical research on cannabinoids and cancer has continued to expand, though clinical translation remains limited.

The bigger picture

The concept of cannabinoids as multi-modal anti-cancer agents, addressing tumor growth, blood supply, spreading, and symptom management simultaneously, has driven considerable research interest. However, clinical evidence for anti-cancer effects remains limited despite strong preclinical data.

Questions still open

Can the anti-angiogenic and anti-metastatic effects of cannabinoids be achieved at clinically tolerable doses? Which cancer types are most susceptible to endocannabinoid-mediated growth inhibition?

Common questions

Can cannabinoids cure cancer?

There is no clinical evidence that cannabinoids cure cancer in humans. This review describes preclinical (laboratory and animal) research showing endocannabinoids can inhibit tumor growth, block blood vessel formation, and reduce metastasis. These findings have not been confirmed in human cancer patients.

How might cannabinoids fight cancer?

Research shows endocannabinoids can act through multiple mechanisms: directly killing cancer cells, blocking formation of new blood vessels that tumors need (angiogenesis), preventing cancer cell migration, and inhibiting metastasis. They also help manage cancer symptoms (pain, nausea, appetite loss).

Read the original research

Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review).

Oncology reports, 17(4), 813-6

View on PubMed ↗

Citation

Bifulco, Maurizio; Laezza, Chiara; Gazzerro, Patrizia; Pentimalli, Francesca. (2007). Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review).. Oncology reports, 17(4), 813-6.